Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Clock Ticks For FDA Decision On First OTC Acne Ingredient NDA

Executive Summary

Under PDUFA timelines for supplemental NDAs, FDA has until sometime in June to make a decision on Galderma Labs' application to switch its acne treatment adapalene, which would make it the first nonprescription product intended to do more than treat the condition at the surface of the skin. An FDA panel unanimously recommended allowing OTC status.

You may also be interested in...



Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval

Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.

Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval

Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.

Galderma Pioneers NDA Path Into OTC Acne Treatment Market

FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical for treatment of acne by consumers 12 years old and up.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel